186 related articles for article (PubMed ID: 21090588)
1. Efavirenz binding site in HIV-1 reverse transcriptase monomers.
Braz VA; Barkley MD; Jockusch RA; Wintrode PL
Biochemistry; 2010 Dec; 49(49):10565-73. PubMed ID: 21090588
[TBL] [Abstract][Full Text] [Related]
2. Efavirenz binding to HIV-1 reverse transcriptase monomers and dimers.
Braz VA; Holladay LA; Barkley MD
Biochemistry; 2010 Jan; 49(3):601-10. PubMed ID: 20039714
[TBL] [Abstract][Full Text] [Related]
3. Allosteric suppression of HIV-1 reverse transcriptase structural dynamics upon inhibitor binding.
Seckler JM; Barkley MD; Wintrode PL
Biophys J; 2011 Jan; 100(1):144-53. PubMed ID: 21190666
[TBL] [Abstract][Full Text] [Related]
4. Effects of efavirenz binding on the subunit equilibria of HIV-1 reverse transcriptase.
Venezia CF; Howard KJ; Ignatov ME; Holladay LA; Barkley MD
Biochemistry; 2006 Mar; 45(9):2779-89. PubMed ID: 16503633
[TBL] [Abstract][Full Text] [Related]
5. The HIV-1 p66 homodimeric RT exhibits different conformations in the binding-competent and -incompetent NNRTI site.
Sharaf NG; Xi Z; Ishima R; Gronenborn AM
Proteins; 2017 Dec; 85(12):2191-2197. PubMed ID: 28905420
[TBL] [Abstract][Full Text] [Related]
6. p66/p51 and p51/p51 recombinant forms of reverse transcriptase from human immunodeficiency virus type 1--interactions with primer tRNA(Lys3), initiation of cDNA synthesis, and effect of inhibitors.
Dufour E; El Dirani-Diab R; Boulmé F; Fournier M; Nevinsky G; Tarrago-Litvak L; Litvak S; Andreola ML
Eur J Biochem; 1998 Jan; 251(1-2):487-95. PubMed ID: 9492322
[TBL] [Abstract][Full Text] [Related]
7. Impact of residues in the nonnucleoside reverse transcriptase inhibitor binding pocket on HIV-1 reverse transcriptase heterodimer stability.
Figueiredo A; Zelina S; Sluis-Cremer N; Tachedjian G
Curr HIV Res; 2008 Mar; 6(2):130-7. PubMed ID: 18336260
[TBL] [Abstract][Full Text] [Related]
8. Identification of amino acid residues in the human immunodeficiency virus type-1 reverse transcriptase tryptophan-repeat motif that are required for subunit interaction using infectious virions.
Mulky A; Sarafianos SG; Jia Y; Arnold E; Kappes JC
J Mol Biol; 2005 Jun; 349(4):673-84. PubMed ID: 15893326
[TBL] [Abstract][Full Text] [Related]
9. The N348I mutation at the connection subdomain of HIV-1 reverse transcriptase decreases binding to nevirapine.
Schuckmann MM; Marchand B; Hachiya A; Kodama EN; Kirby KA; Singh K; Sarafianos SG
J Biol Chem; 2010 Dec; 285(49):38700-9. PubMed ID: 20876531
[TBL] [Abstract][Full Text] [Related]
10. The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors.
Balzarini J; Auwerx J; Rodríguez-Barrios F; Chedad A; Farkas V; Ceccherini-Silberstein F; García-Aparicio C; Velázquez S; De Clercq E; Perno CF; Camarasa MJ; Gago F
Mol Pharmacol; 2005 Jul; 68(1):49-60. PubMed ID: 15833734
[TBL] [Abstract][Full Text] [Related]
11. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[Spiro[4"-amino-2",2" -dioxo-1",2" -oxathiole-5",3'-[2', 5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]]]-3-ethylthy mine.
Sluis-Cremer N; Dmitrienko GI; Balzarini J; Camarasa MJ; Parniak MA
Biochemistry; 2000 Feb; 39(6):1427-33. PubMed ID: 10684624
[TBL] [Abstract][Full Text] [Related]
12. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding.
Sluis-Cremer N; Temiz NA; Bahar I
Curr HIV Res; 2004 Oct; 2(4):323-32. PubMed ID: 15544453
[TBL] [Abstract][Full Text] [Related]
13. Non-nucleoside Reverse Transcriptase Inhibitors Inhibit Reverse Transcriptase through a Mutually Exclusive Interaction with Divalent Cation-dNTP Complexes.
DeStefano JJ
Biochemistry; 2019 Apr; 58(16):2176-2187. PubMed ID: 30900874
[TBL] [Abstract][Full Text] [Related]
14. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 (HIV-1) reverse transcriptase are instrumental to maintain catalytic activity and to design new classes of anti-HIV-1 drugs.
Auwerx J; Van Nieuwenhove J; Rodríguez-Barrios F; de Castro S; Velázquez S; Ceccherini-Silberstein F; De Clercq E; Camarasa MJ; Perno CF; Gago F; Balzarini J
FEBS Lett; 2005 Apr; 579(11):2294-300. PubMed ID: 15848161
[TBL] [Abstract][Full Text] [Related]
15. Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant.
Das K; Ding J; Hsiou Y; Clark AD; Moereels H; Koymans L; Andries K; Pauwels R; Janssen PA; Boyer PL; Clark P; Smith RH; Kroeger Smith MB; Michejda CJ; Hughes SH; Arnold E
J Mol Biol; 1996 Dec; 264(5):1085-100. PubMed ID: 9000632
[TBL] [Abstract][Full Text] [Related]
16. Homodimerization of the p51 subunit of HIV-1 reverse transcriptase.
Zheng X; Mueller GA; Cuneo MJ; Derose EF; London RE
Biochemistry; 2010 Apr; 49(13):2821-33. PubMed ID: 20180596
[TBL] [Abstract][Full Text] [Related]
17. Solution structural dynamics of HIV-1 reverse transcriptase heterodimer.
Seckler JM; Howard KJ; Barkley MD; Wintrode PL
Biochemistry; 2009 Aug; 48(32):7646-55. PubMed ID: 19594135
[TBL] [Abstract][Full Text] [Related]
18. Differential isotopic enrichment to facilitate characterization of asymmetric multimeric proteins using hydrogen/deuterium exchange mass spectrometry.
Goswami D; Tuske S; Pascal BD; Bauman JD; Patel D; Arnold E; Griffin PR
Anal Chem; 2015 Apr; 87(7):4015-4022. PubMed ID: 25763479
[TBL] [Abstract][Full Text] [Related]
19. Thumbs down for HIV: domain level rearrangements do occur in the NNRTI-bound HIV-1 reverse transcriptase.
Wright DW; Sadiq SK; De Fabritiis G; Coveney PV
J Am Chem Soc; 2012 Aug; 134(31):12885-8. PubMed ID: 22827470
[TBL] [Abstract][Full Text] [Related]
20. Mechanism of allosteric inhibition of HIV-1 reverse transcriptase revealed by single-molecule and ensemble fluorescence.
Schauer GD; Huber KD; Leuba SH; Sluis-Cremer N
Nucleic Acids Res; 2014 Oct; 42(18):11687-96. PubMed ID: 25232099
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
